Partnering With Us

We believe that through collaboration, we can advance drug discovery and development to make a real difference in the lives of patients. With our own investments into proprietary technology platforms forming the basis for highly cost effective R&D in a joint ecosystem, we focus on data-driven precision medicine and early disease relevance to drive up probabilities of success (PoS). Within our pipeline co-creation model, our partners benefit from flexible access to our state-of-the art technology platforms and experienced researchers and scientists to generate R&D returns and therapeutics from their variable costs forming a shared R&D economy. 

Always with the end goal in mind, we form result-driven partnerships to co-create assets and intellectual property by leveraging Evotec assets, targets, and propriety technology platforms together with our partners' for co-development or new co-creation. With our state-of-the art solutions, built always with the highest quality standards and on top of our successful track record, we bring a capital-efficient model to drug discovery and development for medicines that matter. 

>500

Partners across shared R&D economy working in parallel on our platform

>50

Compounds that have been approved for clinical trials

~10%

Year over year growth in customer base

>90%

Repeat business

~50%

More cost efficient

~30%

Time saved to IND

>500

Partners across shared R&D economy working in parallel on our platform

>50

Compounds that have been approved for clinical trials

~10%

Year over year growth in customer base

>90%

Repeat business

~50%

More cost efficient

~30%

Time saved to IND

TODO

Pipeline Co-Creation

Matthias Evers

Dr Matthias Evers

Chief Business Officer

vCard
Logo Evotec white
Evotec has the right technologies & disease understanding to meet our partners' evolving needs: a comprehensive disease knowledge at the molecular level, cutting-edge technologies & platforms to translate this expertise into effective precision medicines.